{
    "title": "112_s1206",
    "content": "The \"Medicare Drug Savings Act of 2011\" requires drug manufacturers to provide rebates for drugs dispensed to low-income individuals. The \"Medicare Drug Savings Act of 2011\" mandates drug manufacturers to offer rebates for drugs dispensed to low-income individuals. Section 1860D-2 of the Social Security Act is amended to include a Prescription Drug Rebate Agreement requirement for covered part D drugs starting in 2013. The \"Medicare Drug Savings Act of 2011\" mandates drug manufacturers to offer rebates for drugs dispensed to low-income individuals. Manufacturers who do not enter into a rebate agreement for the specified period will have their products excluded as a 'covered part D drug' for the following plan year. The rebate agreement requires manufacturers to provide rebates for covered part D drugs dispensed to rebate eligible individuals after a certain date. The Medicare Drug Savings Act of 2011 requires drug manufacturers to offer rebates for drugs dispensed to low-income individuals. Manufacturers must enter into a rebate agreement and provide rebates for covered part D drugs. The rebate must be paid to the Secretary within 30 days of receiving the required information. The Secretary will establish terms and conditions for compliance, penalties, and program evaluations similar to rebate agreements under the Act. The Medicare Drug Savings Act of 2011 mandates drug manufacturers to offer rebates for drugs dispensed to low-income individuals. Manufacturers must enter into a rebate agreement and provide rebates for covered part D drugs. The rebate amount is based on the total number of units of the drug dispensed to rebate eligible individuals. The Medicare Drug Savings Act of 2011 requires drug manufacturers to offer rebates for drugs dispensed to low-income individuals, based on the total units dispensed. Rebates are calculated by comparing Medicaid rebate amounts to Medicare drug program rebate eligible amounts. The Medicaid rebate amount is determined based on the dosage form and strength of a covered part D drug provided by the manufacturer for a rebate period. It varies depending on whether the drug is a single source or innovator multiple source drug, or any other covered outpatient drug. The average Medicare drug program rebate eligible rebate amount is calculated for each dosage form and strength of a covered part D drug provided by a manufacturer for a rebate period. It includes the sum of all rebates, discounts, or other price concessions for all PDP sponsors under part D and MA organizations administering an MA-PD plan under part C. The average Medicare drug program rebate eligible amount is calculated for each dosage form and strength of a covered part D drug, based on per-unit basis and applicable to rebate eligible Medicare drug plan enrollees and PDP and MA-PD enrollees. The average Medicare drug program rebate eligible amount is calculated based on the number of units dispensed to eligible individuals enrolled in prescription drug plans administered by PDP sponsors or MA organizations, divided by the total number of units dispensed to all eligible individuals in these plans. The Secretary may establish a methodology for estimating average Medicare drug program rebate eligible amounts for each rebate period based on bid and utilization information. If estimates are used, a reconciliation process will be established for adjusting manufacturer rebate payments within 3 months. The Secretary will establish terms and conditions for rebate agreements under this subsection, including compliance requirements. Definitions for rebate eligible individuals will also be provided. The Secretary will establish terms and conditions for rebate agreements under this subsection, including compliance requirements for subsidy eligible individuals, Medicaid beneficiaries, and part D eligible individuals. The term 'rebate period' is defined in section 1927(k)(8). The curr_chunk discusses the reporting requirement for the determination and payment of rebates by manufacturers related to rebate eligible Medicare drug plan enrollees. It outlines the requirements for PDP sponsors to comply with specific regulations for contract years starting on or after January 1, 2013. PDP sponsors must report information on drug units, prices, discounts, and rebates to manufacturers for Medicare drug plan enrollees. PDP sponsors must report information on drug units, prices, discounts, and rebates to manufacturers for Medicare drug plan enrollees, including details on price discounts, concessions, and rebates for different enrollees. Additional information may be required by the Secretary to calculate average rebate amounts and determine required rebates for specific drugs. PDP sponsors must report drug unit information, prices, discounts, and rebates to the Secretary in a standard format for audit oversight. Confidentiality rules apply to the reported information similar to those for manufacturers and wholesalers. The paragraph discusses the oversight of information reported by PDP sponsors to the Secretary, which can be used by the Inspector General of the Department of Health and Human Services for audit, investigation, and evaluations. The paragraph outlines penalties for PDP sponsors who fail to provide timely information or provide false information, including civil money penalties of $10,000 per day for late information and up to $100,000 for each item of false information. The paragraph outlines civil money penalties for PDP sponsors who fail to provide timely or accurate information, in addition to other prescribed penalties. The penalties are outlined in section 1128A and apply to MA organizations as well. Additionally, there is a reporting requirement related to rebates for Medicare drug plan enrollees, and rebates are deposited into the Medicare Prescription Drug Account. Section 1860D-16(c) of the Social Security Act is amended to include a rebate provision for Medicare drug plan enrollees. This amendment excludes rebate amounts from the determination of best price and average manufacturer price under Medicaid. The Social Security Act is amended to include rebate provisions for Medicare drug plan enrollees, excluding rebate amounts from best price and average manufacturer price determinations under Medicaid. Amendments include changes to subclauses (IV) and (V), and the addition of a new subclause (VI) for amounts paid under rebate agreements."
}